Bladder cancer

Gene expression profile and enrichment pathways in different stages of bladder cancer

Z. - Q. Fang, Zang, W. - D., Chen, R., Ye, B. - W., Wang, X. - W., Yi, S. - H., Chen, W., He, F., and Ye, G., Gene expression profile and enrichment pathways in different stages of bladder cancer, vol. 12, pp. 1479-1489, 2013.

Bladder cancer is a highly heterogeneous neoplasm. We examined the gene expression profile in 3 bladder cancer stages (Ta, T1, T2) using expression microarray analysis of 40 bladder tumors. Differentially expressed genes were found by the t-test, with ANXA5, ATP6V1B2, CTGF, GEM, IL13RA1, and LCP1); 5 genes were up-regulated at the Ta-T1 stage, but down-regulated at the T1-T2 stage (ACPP, GNL1, RIPK1, RAPGEF3, and ZER1).

CCR2-64I is a risk factor for development of bladder cancer

K. F. Narter, Agachan, B., Sozen, S., Cincin, Z. B., and Isbir, T., CCR2-64I is a risk factor for development of bladder cancer, vol. 9, pp. 685-692, 2010.

Chemokines are potent proinflammatory cytokines that are implicated in numerous inflammatory diseases. Proinflammatory gene polymorphisms lead to variations in the production and concentration of inflammatory proteins. We investigated a possible association between polymorphisms in chemokine and chemokine receptor genes (MCP-1 A-2518G and CCR2-V64I) and bladder cancer risk. Genotypes were determined by PCR-RFLP assays in 72 bladder cancer patients and 76 unrelated age-matched healthy controls.

Meta-analysis of epidemiological studies of association of P53 codon 72 polymorphism with bladder cancer

D. B. Li, Wei, X., Jiang, L. H., Wang, Y., and Xu, F., Meta-analysis of epidemiological studies of association of P53 codon 72 polymorphism with bladder cancer, vol. 9, pp. 1599-1605, 2010.

Although there have been many studies investigating a possible association between p53 codon 72 polymorphism and risk of bladder cancer, the results have been inconsistent. We conducted a meta-analysis of six epidemiological studies, which included 597 bladder cancer cases and 731 controls. Patients with bladder cancer had a significantly lower frequency of Pro/Arg [odds ratio (OR) = 0.80, 95% confidence interval (CI) = 0.64-0.99], when compared to controls.

Pages

Subscribe to Bladder cancer